- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00045370
Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
A Phase I Study of the Safety, Tolerability, and Antitumor Activity of Escalating Doses of Intravenous CCI-779 Given in Combination With Escalating Doses of Interferon-Alpha to Patients With Advanced Renal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as interferon alfa use different ways to stimulate the immune system and stop cancer cells from growing. Combining biological therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combining chemotherapy with biological therapy in treating patients who have locally advanced or metastatic kidney cancer.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
OBJECTIVES:
- Determine the maximum tolerated dose of CCI-779 in combination with interferon alfa in patients with locally advanced or metastatic renal cell cancer.
- Determine the safety and tolerability of this regimen in these patients.
- Determine, preliminarily, any antitumor activity of this regimen in these patients.
- Determine the pharmacokinetics of this regimen in these patients.
OUTLINE: This is a dose-escalation, multicenter study.
Patients receive interferon alfa (IFN-A) subcutaneously 3 times a week. Beginning on week 2, patients also receive CCI-779 IV over 30 minutes once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
Cohorts of at least 6 patients receive escalating doses of CCI-779 and then IFN-A until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 20 additional patients are treated at that dose level.
Patients are followed at 30 days.
PROJECTED ACCRUAL: Approximately 50 patients will be accrued for this study.
Tipo de estudo
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
New York
-
New York, New York, Estados Unidos, 10021
- Memorial Sloan-Kettering Cancer Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
DISEASE CHARACTERISTICS:
Histologically confirmed locally advanced or metastatic renal cell cancer
- Progressive disease after treatment with 0-2 courses of immunotherapy, chemotherapy, or other systemic therapy for advanced disease
- Measurable or evaluable disease
No concurrent CNS metastases
- Prior CNS metastases allowed if no residual disease by MRI
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-1
Life expectancy
- At least 3 months
Hematopoietic
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 9 g/dL
Hepatic
- Bilirubin no greater than 1.5 mg/dL
- AST and ALT no greater than 3 times upper limit of normal (ULN) (5 times ULN if liver metastases present)
Renal
- Creatinine less than 2 mg/dL OR
- Creatinine clearance at least 60 mL/min
Cardiovascular
- No unstable angina
- No myocardial infarction within the past 6 months
Other
- Cholesterol no greater than 350 mg/dL
- Triglycerides no greater than 400 mg/dL
- HIV negative
- Not immunocompromised
- No active autoimmune disorder
- No active infection requiring antibiotic therapy
- No other serious concurrent illness
- No known hypersensitivity to components of CCI-779, interferon alfa, diphenhydramine hydrochloride, or both acetaminophen and nonsteroidal anti- inflammatory drugs
- No other major illness that would preclude study participation
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
- At least 3 weeks since prior immunotherapy
- No prior interferon alfa
- No other concurrent immunotherapy
- No prophylactic growth factors
- Concurrent epoetin alfa allowed
Chemotherapy
- See Disease Characteristics
- At least 3 weeks since prior chemotherapy
- No prior CCI-779
- No other concurrent chemotherapy
Endocrine therapy
- No concurrent hormonal therapy for malignancy (megestrol for appetite loss allowed)
- Concurrent inhaled or replacement steroids allowed
Radiotherapy
- At least 3 weeks since prior radiotherapy
- No concurrent radiotherapy
Surgery
- At least 3 weeks since prior surgery
Other
- See Disease Characteristics
- At least 3 weeks since prior immunosuppressive agents
- At least 4 weeks since prior investigational agents
- No other concurrent investigational agents
- No concurrent immunosuppressive therapy
- No concurrent anticonvulsants known to be cytochrome P450 inducers, ketoconazole, diltiazem, rifampin, terfenadine, cisapride, astemizole, or pimozide
- No concurrent maintenance therapy for life-threatening ventricular arrhythmia
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias por Tipo Histológico
- Neoplasias
- Neoplasias Urológicas
- Neoplasias urogenitais
- Neoplasias por local
- Doenças renais
- Doenças Urológicas
- Adenocarcinoma
- Carcinoma
- Neoplasias Glandulares e Epiteliais
- Neoplasias Renais
- Carcinoma de Células Renais
- Efeitos Fisiológicos das Drogas
- Agentes Anti-Infecciosos
- Antivirais
- Agentes Antineoplásicos
- Agentes imunossupressores
- Fatores imunológicos
- Agentes antibacterianos
- Antibióticos, Antineoplásicos
- Antifúngicos
- Interferons
- Interferon-alfa
- Sirolimo
Outros números de identificação do estudo
- 02-023
- CDR0000256468 (Identificador de registro: PDQ (Physician Data Query))
- NCI-G02-2104
- W-AR-3066K1-124-US
- WYETH-C-C0125-32
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .